report better-than-expect sale ep result rais guidanc
organ sale impress driven medsurg segment
partial off-set neurotech spine orthoped
stryker portfolio move past decad clearli help move
compani organ growth rate higher dont think quarter go-
forward sale growth run-rat set difficult comp next year still believ
well posit deliv growth peer believ
premium valuat remain warrant maintain overweight rate
share gain orthoped continu view knee hip busi
deliv growth constant currenc global respect
market thu gain share mako robot system well
print product continu aid result zimmer biomet receiv fda clearanc
rosa system total knee applic seem impact
result total knee procedur y/i order book manag
comment robust
beauti diversif continu despit continu focu
street knee franchis mako well-diversifi compani evid
quarter growth across three unit medsurg deliv impress
organ growth reflect past decad portfolio action shift higher
growth though acknowledg rate unlik sustain longer term
rais ep estim price target maintain overweight rais
ep price target methodolog remain base
forward pe target vs prior roll forward target year
ep estim yield higher price target prior
trade ep believ premium growth deserv
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
overweight believ sustain
above-sector revenu growth profil see
multipl driver across three busi
believ deliv margin commit
goal least annual drive least
ep growth given outlook believ
premium pe justifi
growth greater success new product
greater success drive oper margin
downsid case driver includ slowdown
orthoped hospit capital-expenditure market increas
competit knee foreign exchang stronger
us dollar inabl drive margin expans
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
sale ep strong street estim stryker
organ sale growth primarili driven medsurg busi
ep y/i street estim
compani guidanc rang increas
organ sale growth adjust ep rang
net/net view quarter outlook strong continu
rate overweight believ stock remain worthi premium valuat
million except per share data chang sale constant currenc organ basi unless otherwis note
addit detail quarter
sale came expect organ growth impress
given ytd perform rais sale ep forecast
medsurg organ strong growth across divis us
instrument led growth robust growth power tool wast
manag cite benefit sale forc split
mako us total knee procedur exceed increas prior
year total mako procedur total manag comment
order book continu strong impact competit
gross margin y/i product effici gain
off-set headwind busi mix fx price
oper margin y/i benefit expens manag
mute deal-rel dilut re-affirmed target
oper margin expans year
sale organ basi organ growth divis
medsurg neurotechnolog spine orthoped
gross margin y/i
sg margin y/i continu focu oper
expens improv partial off-set impact acquisit
 margin y/i
oper margin y/i
adjust tax rate y/i favor impact benefit
adjust ep street estim estim
high end guidanc
expect ep bracket street estim fx expect minim impact ep
reflect guidanc
stryker expect organ sale growth rang prior fx expect approxim
neg impact ep unchang full year expect adjust ep versu prior guidanc
manag continu expect oper margin expans higher ep guidanc reflect higher level sale
well tax rate trend toward low end rang
actual million salesrptdex barclay stryker corp
addit color quarter perform pleas see note publish
kstew call note focu mako see competit impact
model avail barclay live
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
